ArticleDrugs2026
Small Molecules Prescribed On- and Off-Label for Thoracic Cancers During Pregnancy: A Combined VigiBase and Systematic Review Analysis.
Article in Drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThoracic cancers during pregnancy are rare but increasingly encountered because of delayed childbearing and the rising incidence of cancer in younger individuals. Despite guideline recommendations, exposure to targeted small-molecule therapies occurs across all trimesters, but safety data remain limited.
objectiveTo investigate the safety of targeted small-molecule therapies for thoracic cancers during pregnancy by combining VigiBase data with a systematic review. PATIENTS AND
methodsWe performed a pharmacovigilance disproportionality analysis based on the reporting odds ratio (ROR) and a systematic review. Individual case safety reports from VigiBase (January 1, 2006-February 24, 2026) were analysed. A systematic review of PubMed, EMBASE, and Scopus through June 25, 2026 included case reports and case series.
resultsThe VigiBase analysis included 15,023 reports of anticancer exposure during pregnancy, of which 162 involved small molecules currently used on- and off-label for thoracic cancers, including 75 with approved agents for non-small-cell lung cancer (NSCLC). Compared with other anticancer agents, including cytotoxic drugs, immune checkpoint inhibitors, other immunotherapies, antibody-drug conjugates, molecularly targeted therapies (including biologics and small molecules other than those of interest), and anticancer agents not further specified, the small molecules of interest were associated with disproportionate reporting of premature labor (ROR: 2.64; 95% confidence interval [CI]: 1.21-5.75), foetal growth restriction (ROR: 2.10; 95% CI 1.15-3.84), neonatal respiratory distress syndrome (ROR: 3.78; 95% CI 1.50-9.57), and low birth weight (ROR: 2.27; 95% CI 1.18-4.37). Among approved small molecules for NSCLC, signals were observed for premature labor (ROR: 4.17; 95% CI 1.65-10.53), neonatal respiratory complications (ROR: 2.56; 95% CI 1.02-6.42), and low birth weight (ROR: 3.55; 95% CI 1.61-7.83). Of note, anaplastic lymphoma kinase (ALK) inhibitor ICSRs were fewer, and 14/18 alectinib reports described pregnancy exposure without pregnancy-related ADRs of interest, precluding alectinib-specific disproportionality analysis. The systematic review included 26 women (27 pregnancies) with oncogene-driven metastatic NSCLC. Live births occurred in 96.3% of pregnancies, with 53.8% preterm deliveries, 33.3% pregnancy complications, and 19.2% neonatal complications. Maternal outcomes were favourable (objective response rate 80.8%). There were no clinically significant pregnancy complications reported in the 10 cases involving alectinib exposure alone.
conclusionsExposure during pregnancy to small molecules currently used on- and off-label for thoracic cancers was associated with disproportionate reporting signals for selected adverse foetal outcomes. The available clinical evidence remains limited, and although no clinically significant pregnancy complications were reported with alectinib exposure, the current data are insufficient to establish its safety. Treatment decisions should therefore be individualised and made within a multidisciplinary expert setting.
Identifiers
42911352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.